/EKTAY

EKTAY Stock - Elekta AB (publ)

Q: What is the analyst price target for EKTAY?

Analyst price target information is not currently available for EKTAY.

Q: What is EKTAY's market cap?

Market capitalization information is not currently available for EKTAY.

Healthcare|Medical - Instruments & Supplies|OTC

$6.04+0.50%

+$0.03 (+0.50%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $6.64

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for EKTAY

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2021

FY2022

FY2023

FY2024

FY2025

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.06

52W High$6.29

52W Low$4.35

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$18.02B	$18.12B	$16.87B	$14.55B	$13.76B
Gross Profit	$6.75B	$6.80B	$6.35B	$5.44B	$5.61B
Gross Margin	37.4%	37.5%	37.6%	37.4%	40.8%
Operating Income	$890.00M	$2.04B	$1.43B	$1.64B	$1.91B
Net Income	$237.00M	$1.30B	$943.00M	$1.15B	$1.25B
Net Margin	1.3%	7.2%	5.6%	7.9%	9.1%
EPS	$0.62	$3.41	$2.47	$3.02	$3.28

Company Overview

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac technology; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy; treatment management solutions; automated and integrated quality assurance solutions; and hardware and software motion management technology. It also provides MOSAIQ Plaza for multidisciplinary cancer care; Elekta Axis Cloud, a managed hosting service; Elekta Studio, an image-guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the radiation oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Geneva, an applicator for cervical cancer treatment. In addition, the company offers Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for neurosurgeons; Leksell Gamma Knife Lightning for accelerated radiosurgery. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System or minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

Hold / Neutral

Sell / Underperform

100%

Analyst Consensus🔴 Bearish

0 Bullish2 Neutral/Bearish

Price Targets

No price targets available

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
October 5th 2023	Barclays	Initiation	Underweight	-
July 12th 2023	Goldman	Initiation	Sell	-
December 12th 2022	Citigroup	Initiation	Sell	-
October 18th 2022	Morgan Stanley	Initiation	Underweight	-

Earnings History & Surprises

EKTAY

Beat Rate

Last 2 quarters

Avg Surprise

-13.2%

EPS vs Estimate

Beats / Misses

0/2

Last 12 quarters

Latest EPS

$0.07

Q4 2025

EPS Surprise History

Q1 24

No data

Q2 24

No data

Q3 24

No data

Q4 24

No data

Q1 25

-11.1%

$0.08vs$0.09

Q2 25

-15.4%

$0.11vs$0.13

Q3 25

No data

Q4 25

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 28, 2026	—	—	—	—
Q1 2026	Feb 20, 2026	—	—	—	—
Q4 2025	Nov 26, 2025	—	$0.07	—	—
Q3 2025	Aug 28, 2025	—	$0.03	—	—
Q2 2025	May 28, 2025	$0.13	$0.11	-15.4%	✗ MISS
Q1 2025	Feb 21, 2025	$0.09	$0.08	-11.1%	✗ MISS
Q4 2024	Nov 27, 2024	—	$0.06	—	—
Q3 2024	Aug 28, 2024	—	$0.04	—	—
Q2 2024	Jun 5, 2024	—	$0.11	—	—
Q1 2024	Feb 29, 2024	—	$0.08	—	—
Q4 2023	Nov 30, 2023	—	$0.09	—	—
Q3 2023	Aug 24, 2023	—	$0.06	—	—
Q2 2023	May 25, 2023	—	$0.15	—	—
Q1 2023	Feb 24, 2023	—	$0.08	—	—
Q4 2022	Nov 24, 2022	—	$0.05	—	—
Q3 2022	Aug 25, 2022	—	$0.02	—	—
Q2 2022	May 25, 2022	—	$0.12	—	—
Q1 2022	Feb 24, 2022	—	$0.07	—	—
Q4 2021	Nov 25, 2021	—	$0.12	—	—
Q3 2021	Aug 25, 2021	—	$0.04	—	—

Frequently Asked Questions about EKTAY

What is EKTAY's current stock price?

Elekta AB (publ) (EKTAY) is currently trading at $6.04 per share. The stock has moved +0.50% today.

What is the analyst price target for EKTAY?

No analyst price targets are currently available for this stock.

What sector is Elekta AB (publ) in?

Elekta AB (publ) operates in the Healthcare sector, specifically within the Medical - Instruments & Supplies industry. The company is traded on the OTC exchange.

What is EKTAY's market cap?

Elekta AB (publ) has a market capitalization of $2.38 billion, making it a mid-cap company.

Does EKTAY pay dividends?

No, Elekta AB (publ) does not currently pay a dividend to shareholders.